Pharmaceutical Executive December 19, 2025
BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and is expected to immediately accelerate revenue growth while strengthening long-term financial performance.
BioMarin Pharmaceuticals entered into a definitive agreement to acquire Amicus Therapeutics to expand its position in rare diseases, increase revenue growth, and strengthen the company’s financial outlook.
The boards of both companies unanimously approved the agreement, and Amicus’ board of directors unanimously recommended that Amicus’ stockholders vote to adopt the agreement.1
“Amicus, like BioMarin, is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its founding, developing and bringing to market important therapies for individuals living...
Today's Sponsors
Today's Sponsor